Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509026 | 0.86 | CES1 (0.39) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL2304592 | 0.79 | CHRM5 (0.43) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL18954585 | 0.79 | ALDH1A1 (0.43) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL2816698 | 0.77 | ALDH1A1 (0.65) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL29785238 | 0.77 | ALDH1A1 (0.65) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL1058865 | 0.76 | TRPA1 (0.64) | CHRM5ALDH1A1MEN1KMT2ATRPA1 | |
| SCHEMBL22041008 | 0.74 | MAPT (0.43) | MEN1KMT2ATRPA1MAPTPGR | |
| SCHEMBL12930261 | 0.73 | CHRM5 (0.53) | CHRM5ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL24718014 | 0.72 | TGM2 (0.36) | ALDH1A1MEN1KMT2AMAPTPGR | |
| SCHEMBL5001267 | 0.72 | CHRM5 (0.60) | CHRM5ALDH1A1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | CHRM5 2168/4885ALDH1A1 894/4885MEN1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.